Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04535882

Enrollment

673

Registered

2020-09-02

Start date

2020-10-01

Completion date

2026-07-31

Last updated

2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LRG Levels

Brief summary

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Detailed description

Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group. CD patients whose CDAI \>150 were divided into the active CD group.

Interventions

DIAGNOSTIC_TESTserum leucine-rich alpha-2 glycoprotein (LRG) levels

Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients whom possible UC or Crohn disease was suspected

Exclusion criteria

* other autoimmune diseases * acute or chronic renal failure * chronic heart diseases * liver cirrhosis * cancer * acute or chronic systemic infections * ischemic colitis

Design outcomes

Primary

Measure	Time frame	Description
Serum LRG measurement	one year	Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026